secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cue Biopharma, Inc. (CUE)
CIK:        0001645460
Form:       8-K
Filed at:   2026-06-02T20:45:51+00:00
Accession:  0001193125-26-253709
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Cue Biopharma appoints new directors, chief legal officer, and accounting officer; board size reduced
--------------------------------------------------------------------------------

- Resignations of directors Jill Broadfoot, Peter Kiener, Frank Morich, and Patrick Verheyen effective May 29, 2026.
- Sumita Ray appointed Chief Legal & Compliance Officer and Corporate Secretary on June 1, 2026.
- Michael Meluzio appointed VP, Principal Accounting Officer on June 1, 2026.
- Daniel Camardo and Viola Meehan appointed as directors on May 30, 2026; board reduced from seven to five.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645460/000119312526253709/0001193125-26-253709-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645460/000119312526253709/d139032d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-253709

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer